Genocea commences Phase 1/2a study of GEN-003
Linkedin

Genocea commences Phase 1/2a study of GEN-003

London : United Kingdom | Aug 16, 2012 at 6:55 AM PDT
Source: Pharmaceutical Industry News
XX XX
Views: Pending
 
The double-blind, dose escalation trial will enrol approximately 150 volunteers with moderate-to-severe HSV-2 infection who are otherwise healthy. The placebo-controlled study is designed to evaluate the safety and tolerability of GEN-003 and its ability to stimulate the immune system, in... FULL ARTICLE AT Pharmaceutical Industry News
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.